Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal

LONDON (Reuters) – For Christophe Weber, the boss of Japan’s Takeda Pharmaceutical , securing a $62 billion deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit.

…read more

Discover Tomorrow’s Winning Stocks!
Get our latest stock reports before everyone else! Actionable news, and breakout stocks w multi-bagger upside potential — delivered directly to your inbox.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Source:: Reuters – Business News